Neuravi Strengthens Patent Portfolio For Novel Stent Retrievers With Newly Issued U.S. And European Patents
Published: May 03, 2016
GALWAY, Ireland--(BUSINESS WIRE)--Neuravi, a developer of innovative minimally invasive stroke therapy solutions, announced today that the U.S. Patent and Trademark Office (USPTO) has approved a patent providing additional coverage of the company’s therapeutic stent-retriever platform for the endovascular treatment of acute ischemic stroke. Earlier this year, Neuravi also received a European patent grant for this platform.
“Our extensive patent portfolio has early priority dates and we continue to strengthen it with key features important to stent retriever performance. We will continue to invest in technology and in clot research to help address the challenges of treating acute ischemic stroke.”
The Neuravi intellectual property estate now extends to 63 U.S. filings, 34 granted patents, one notice of allowance, and 28 pending applications. Outside the United States, Neuravi has multiple pending applications with the European Patent Office, in China and Japan, and internationally under the Patent Cooperation Treaty.
“Neuravi is committed to innovation that improves clinical outcomes,” said David Vale, chief technology officer, Neuravi. “Our extensive patent portfolio has early priority dates and we continue to strengthen it with key features important to stent retriever performance. We will continue to invest in technology and in clot research to help address the challenges of treating acute ischemic stroke. ”
The design of Neuravi’s EmboTrap® Revascularization device was informed by extensive research on the wide range of different clot types that cause ischemic stroke. Insights from this clot research have added significant value to the innovation process, enhancing the proprietary design of both the EmboTrap and future Neuravi devices in development.
The EmboTrap Revascularization Device is available in Europe to treat patients with acute ischemic stroke. The EmboTrap is not currently approved in the U.S., where it is available for investigational use only in the ARISE II clinical trial.
Neuravi designs, develops and manufactures innovative medical devices for the treatment of acute stroke. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke. More information can be found at www.neuravi.com.